GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer

The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

本临床试验旨在验证免疫治疗产品GSK1572932A用于非小细胞肺癌（Non-Small Cell Lung Cancer）患者肿瘤切除术后的临床获益。该治疗全程需完成13次注射，给药周期跨度为27个月。本试验方案已完成更新，以符合2007年9月颁布的美国食品药品监督管理局（Food and Drug Administration, FDA）修订法案。